ATE326216T1 - Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymer - Google Patents
Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymerInfo
- Publication number
- ATE326216T1 ATE326216T1 AT02732526T AT02732526T ATE326216T1 AT E326216 T1 ATE326216 T1 AT E326216T1 AT 02732526 T AT02732526 T AT 02732526T AT 02732526 T AT02732526 T AT 02732526T AT E326216 T1 ATE326216 T1 AT E326216T1
- Authority
- AT
- Austria
- Prior art keywords
- water
- soluble
- pharmaceutical composition
- composition containing
- active substance
- Prior art date
Links
- 239000004094 surface-active agent Substances 0.000 title abstract 2
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 title 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 title 1
- 229920003169 water-soluble polymer Polymers 0.000 title 1
- 229920000642 polymer Polymers 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000007864 aqueous solution Substances 0.000 abstract 2
- 239000008247 solid mixture Substances 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 239000003945 anionic surfactant Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 abstract 1
- 239000003093 cationic surfactant Substances 0.000 abstract 1
- 239000008297 liquid dosage form Substances 0.000 abstract 1
- 239000007909 solid dosage form Substances 0.000 abstract 1
- 239000000829 suppository Substances 0.000 abstract 1
- 239000003826 tablet Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10114869 | 2001-03-26 | ||
| DE2001117049 DE10117049A1 (de) | 2001-04-05 | 2001-04-05 | Zusammensetzung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE326216T1 true ATE326216T1 (de) | 2006-06-15 |
Family
ID=26008913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02732526T ATE326216T1 (de) | 2001-03-26 | 2002-03-26 | Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymer |
Country Status (14)
| Country | Link |
|---|---|
| US (5) | US20040077232A1 (enExample) |
| EP (1) | EP1372611B1 (enExample) |
| JP (1) | JP4330343B2 (enExample) |
| CN (1) | CN100350911C (enExample) |
| AT (1) | ATE326216T1 (enExample) |
| AU (1) | AU2002304784A1 (enExample) |
| BR (1) | BR0208306A (enExample) |
| CA (1) | CA2439097C (enExample) |
| CY (1) | CY1106159T1 (enExample) |
| DE (1) | DE60211494T2 (enExample) |
| DK (1) | DK1372611T3 (enExample) |
| ES (1) | ES2261671T3 (enExample) |
| PT (1) | PT1372611E (enExample) |
| WO (1) | WO2002076432A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003077883A2 (de) * | 2002-03-15 | 2003-09-25 | Kuyus Stiftung | Zusammensetzung und verwendung derselben zur bildung eines schutzfilms auf nasenschleimhäuten |
| WO2006024494A1 (en) * | 2004-08-31 | 2006-03-09 | Novartis Ag | Use of midostaurin for treating gastrointestinal stromal tumors |
| JO2897B1 (en) | 2004-11-05 | 2015-09-15 | نوفارتيس ايه جي | Organic compounds |
| PT2054040E (pt) * | 2006-08-16 | 2011-06-30 | Novartis Ag | Método para produzir dispersões sólidas de compostos terapêuticos altamente cristalinos |
| JP5161528B2 (ja) * | 2007-10-02 | 2013-03-13 | 浜松ホトニクス株式会社 | パクリタキセル微粒子、パクリタキセル微粒子分散液、および、これらの製造方法 |
| US20090087460A1 (en) * | 2007-10-02 | 2009-04-02 | Hamamatsu Photonics K.K. | Solid composition, microparticles, microparticle dispersion liquid, and manufacturing methods for these |
| JP5149585B2 (ja) * | 2007-10-02 | 2013-02-20 | 浜松ホトニクス株式会社 | 微粒子分散液製造方法 |
| WO2009100176A2 (en) * | 2008-02-07 | 2009-08-13 | Abbott Laboratories | Pharmaceutical dosage form for oral administration of tyrosine kinase inhibitor |
| WO2011000811A2 (en) * | 2009-06-30 | 2011-01-06 | Novartis Ag | Organic compounds |
| WO2013024856A1 (ja) * | 2011-08-17 | 2013-02-21 | 東レ株式会社 | 医療デバイスおよびその製造方法 |
| US10478498B2 (en) | 2014-06-20 | 2019-11-19 | Reform Biologics, Llc | Excipient compounds for biopolymer formulations |
| JP2018501217A (ja) * | 2014-12-02 | 2018-01-18 | 田辺三菱製薬株式会社 | 統合失調症を治療するための２−（（１−（２（４−フルオロフェニル）−２−オキソエチル）ピペリジン−４−イル）メチル）イソインドリン−１−オン |
| KR20170084736A (ko) * | 2016-01-12 | 2017-07-21 | 삼성디스플레이 주식회사 | 표시장치 |
| JP2019527729A (ja) | 2016-07-13 | 2019-10-03 | リフォーム バイオロジクス、エルエルシー | 治療用タンパク質製剤のための安定化賦形剤 |
| US11642199B2 (en) * | 2018-09-24 | 2023-05-09 | 3M Innovative Properties Company | Dental appliance with cosmetic therapeutic aqueous solution |
| CN116370408B (zh) * | 2020-06-17 | 2025-12-02 | 成都瑞沐生物医药科技有限公司 | 一种滴眼给药治疗黄斑水肿、视神经炎和非感染性眼内炎的眼用制剂 |
| WO2024131725A1 (en) * | 2022-12-19 | 2024-06-27 | Shenzhen Pharmacin Co., Ltd. | Topical pharmaceutical compositions and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3754082A (en) * | 1970-06-11 | 1973-08-21 | Richardson Merrell Inc | Process and composition for botfly larvae eliminination |
| CA1141663A (en) * | 1979-09-06 | 1983-02-22 | Yukihisa Ishii | Ophthalmic solution for intraocular pressure adjustment |
| JPS61194034A (ja) * | 1985-02-25 | 1986-08-28 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| JPS632932A (ja) * | 1986-06-23 | 1988-01-07 | Teijin Ltd | 経鼻投与用粉末状組成物 |
| US5093330A (en) * | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US5213738A (en) * | 1990-05-15 | 1993-05-25 | L. Perrigo Company | Method for making a capsule-shaped tablet |
| IT1245761B (it) * | 1991-01-30 | 1994-10-14 | Alfa Wassermann Spa | Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale. |
| GB9325395D0 (en) * | 1993-12-11 | 1994-02-16 | Ciba Geigy Ag | Compositions |
| WO1995022331A1 (en) * | 1994-02-18 | 1995-08-24 | Cephalon, Inc. | Aqueous indolocarbazole solutions |
| EP0733358A3 (de) * | 1995-03-21 | 1998-05-20 | Novartis AG | Intravenös applizierbare Nanosuspensionen |
| EP1004309A4 (en) * | 1997-05-27 | 2001-01-17 | Senju Pharma Co | ISRAPAFANT-CONTAINING AQUEOUS COMPOSITIONS |
| TW546151B (en) * | 1997-07-23 | 2003-08-11 | Senju Pharma Co | Aqueous liquid pharmaceutical composition containing as main component benzopyran derivative |
| DE19813661A1 (de) * | 1997-08-01 | 1999-02-04 | Solvay Pharm Gmbh | Gegen Racemisierung stabilisierte pharmazeutische Zubereitungen von Cilansetron |
| GB9903547D0 (en) * | 1999-02-16 | 1999-04-07 | Novartis Ag | Organic compounds |
| US6190869B1 (en) * | 1999-10-26 | 2001-02-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of protein kinase C-theta expression |
-
2002
- 2002-03-26 EP EP02732526A patent/EP1372611B1/en not_active Expired - Lifetime
- 2002-03-26 ES ES02732526T patent/ES2261671T3/es not_active Expired - Lifetime
- 2002-03-26 US US10/469,757 patent/US20040077232A1/en not_active Abandoned
- 2002-03-26 AT AT02732526T patent/ATE326216T1/de active
- 2002-03-26 AU AU2002304784A patent/AU2002304784A1/en not_active Abandoned
- 2002-03-26 JP JP2002574948A patent/JP4330343B2/ja not_active Expired - Lifetime
- 2002-03-26 CA CA2439097A patent/CA2439097C/en not_active Expired - Fee Related
- 2002-03-26 DE DE60211494T patent/DE60211494T2/de not_active Expired - Lifetime
- 2002-03-26 PT PT02732526T patent/PT1372611E/pt unknown
- 2002-03-26 WO PCT/EP2002/003387 patent/WO2002076432A2/en not_active Ceased
- 2002-03-26 DK DK02732526T patent/DK1372611T3/da active
- 2002-03-26 CN CNB028073460A patent/CN100350911C/zh not_active Expired - Lifetime
- 2002-03-26 BR BR0208306-0A patent/BR0208306A/pt active Search and Examination
-
2006
- 2006-08-03 CY CY20061101092T patent/CY1106159T1/el unknown
-
2008
- 2008-06-26 US US12/147,129 patent/US20080287417A1/en not_active Abandoned
-
2013
- 2013-09-12 US US14/025,219 patent/US20140018346A1/en not_active Abandoned
-
2014
- 2014-06-19 US US14/309,209 patent/US20140303145A1/en not_active Abandoned
-
2016
- 2016-06-20 US US15/186,736 patent/US20160287707A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| PT1372611E (pt) | 2006-08-31 |
| CA2439097C (en) | 2010-10-12 |
| EP1372611B1 (en) | 2006-05-17 |
| JP2004534739A (ja) | 2004-11-18 |
| US20160287707A1 (en) | 2016-10-06 |
| HK1061515A1 (en) | 2004-09-24 |
| EP1372611A2 (en) | 2004-01-02 |
| CA2439097A1 (en) | 2002-10-03 |
| US20080287417A1 (en) | 2008-11-20 |
| JP4330343B2 (ja) | 2009-09-16 |
| CY1106159T1 (el) | 2011-06-08 |
| DE60211494D1 (de) | 2006-06-22 |
| US20040077232A1 (en) | 2004-04-22 |
| WO2002076432A2 (en) | 2002-10-03 |
| WO2002076432A3 (en) | 2002-12-12 |
| BR0208306A (pt) | 2004-03-09 |
| US20140303145A1 (en) | 2014-10-09 |
| DE60211494T2 (de) | 2006-10-12 |
| CN100350911C (zh) | 2007-11-28 |
| CN1499959A (zh) | 2004-05-26 |
| AU2002304784A1 (en) | 2002-10-08 |
| US20140018346A1 (en) | 2014-01-16 |
| DK1372611T3 (da) | 2006-09-18 |
| ES2261671T3 (es) | 2006-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE326216T1 (de) | Pharmazeutische zusammensetzung enthaltend ein schlecht wasserlösliches staurosporin, eine oberflächenaktive substanz und ein wasserlösliches polymer | |
| EE05506B1 (et) | Ravimi manustamise vahend eriti progestiinide jastrogeenide manustamiseks | |
| DE69918310D1 (de) | Tablette mit verzögerter freigabe enthaltend einen blutzuckersenkenden wirkstoff und einen antihyperglyzemischen wirkstoff | |
| ATE292453T1 (de) | Antivirale arznei | |
| ATE356612T1 (de) | Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit | |
| EE200100431A (et) | 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine | |
| WO2003035051A3 (en) | The use of proton sequestering agents in drug formulations | |
| BR0210489A (pt) | Formulação farmacêutica oral, processo para preparar a mesma, uso da mesa, e método para preparar um distúrbio cardiovascular em um paciente | |
| ATE541562T1 (de) | Ibuprofen-suspension | |
| WO2004075875A8 (en) | Dosage form having a saccharide matrix | |
| NO20033305D0 (no) | Nytt filmbelegg | |
| AU2003293593A8 (en) | Pharmaceutical preparations, use of said preparations and method for increasing the bioavailability of medicaments for peroral administration | |
| DE60102590T2 (de) | Darreichungsformen zur behandlung von oralen mykosen | |
| DE50005082D1 (de) | Verfahren zu Herstellung von PULVERFÖRMIGEn SOLUBILISATIONSHILFSSTOFFEn FÜR FESTE PHARMAZEUTISCHE DARREICHUNGSFORMEN | |
| DK1118610T3 (da) | Benzensulfonamid-derivater, fremgangsmåde til fremstilling heraf samt farmaceutiske sammensætninger indeholdende derivaterne | |
| NO20025028L (no) | 9-oksa-epotilonderivater, fremgangsmÕte for fremstilling derav samt deres anvendelse i farmasöytiske preparater | |
| CY1107227T1 (el) | Θεραπεια αυτοανοσων νοσων με εκχυλισμα αμερικανικου γκινσενγκ | |
| ZA200300777B (en) | Process for the preparation of peptide salts, their use and pharmaceutical preparations comprising the peptide salts. | |
| Inoyatov et al. | Preparation and evaluation of a prolonged release pentoxifylline tablet with chitosan | |
| ATE340564T1 (de) | Arzneimittel mit verzögerter wirkstoffabgabe | |
| IL146372A0 (en) | Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives, processes for their preparation, their use and pharmaceutical preparations comprising them | |
| MXPA01011611A (es) | Derivados de espiroimidazolidina, su prepracion, su uso y preparaciones farmaceuticas que los comprenden. | |
| ZA200202426B (en) | Pyrimidine derivatives, process for preparing the derivatives and drugs containing the same as the active ingredient. | |
| Vazquez | Norvir capsules-soon? | |
| Highleyman | ABT-378: A second generation protease inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1372611 Country of ref document: EP |